The primary aim of this trial is to determine the rate of complete response achieved by using Venetoclax and VCD.
Recruitment updated as of June 2019.
Multicentre, single arm, open label trial
Blood and bone marrow samples will be collected as part of the trial, and studied for molecular biomarkers and disease response
TRIAL PRINCIPAL INVESTIGATOR
Professor Andrew Spencer
2018 – 2021
- Alfred Hospital, VIC
- St. George's Hospital, VIC
- PeterMac, VIC
- Austin Hospital, VIC
- Royal Hobart Hospital, TAS
45 newly diagnosed patients with multiple myeloma, who will receive an Autologous Stem Cell Transplant (ASCT)